Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F BMC Neurol. 2013 Jul 11; 13(1):80. Epub 2013 Jul 11. PMID: 23841877. Abstract CommentRecommendBookmarkWatch
